A deeper understanding of the tumor microenvironment (TME) is vital for advancing cancer research and developing therapies. Traditional tumor models remain limited by interspecies differences, variable reproducibility and their inability to replicate the dynamic, multicellular environment of tumors fully. This webinar will explore emerging strategies to address these limitations by introducing a novel co-culture approach that more accurately replicates the tumor microenvironment in vitro.
Tumoroids are derived from patient tumors and maintain the underlying genetic and histological features of the original tissue. They represent a significant advance for personalized oncology and drug testing. However, tumoroid models lack critical stromal and immune components of the TME, limiting their ability to reproduce the cell–cell and cell–matrix interactions that influence tumor progression and treatment response.
In this webinar, the featured speakers will discuss different tumor modeling strategies and share an innovative method that involves co-culturing tumoroids with cancer-associated fibroblasts (CAFs) and immune cells to reconstruct the cellular complexity of the tumor microenvironment in vitro. They will further explain how this new approach brings researchers closer to a true “patient in a dish” for cancer research and next-generation drug development.
Register for this webinar to learn how modeling the tumor microenvironment in vitro supports next-generation cancer research and drug discovery.
Speakers
Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences
Dr. Shawn Fahl is an Immunologist with expertise in flow cytometric and single-cell genomic analysis of complex biological systems. Dr. Fahl trained at the University of Virginia and Fox Chase Cancer Center prior to joining Discovery. He leads the Cell Biology Labs at Discovery, focusing on the processing and analysis of primary human biospecimens and the generation of novel models for therapeutic target and biomarker evaluation.
Message Presenter
Meredith Osborn, Associate Director Product Management, Discovery Life Sciences
Meredith Osborn, MS, is a Biospecimen Expert with over 15 years of experience in FFPE biobanking and other biospecimen solutions. As Associate Director of Product Management, she leads strategic initiatives to develop innovative products, meet research needs and drive thought leadership in the field. Meredith plays a key role in driving Discovery’s adoption of AI technologies to enhance and modernize its pathology workflows.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Cancer and Translational Researchers
- Drug Discovery and Oncology R&D Scientists
- Immuno-oncology Scientists
- Biotech and pharma professionals
What You Will Learn
Attendees will
- Understand the limitations of traditional tumor models and why new in vitro systems are needed
- Learn how co-culturing tumoroids, CAFs and immune cells replicates the tumor micro environment and has the potential to revolutionize cancer research
Xtalks Partner
Discovery Life Sciences
Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of therapeutics and diagnostics that improve patient outcomes. Their extensive portfolio of biospecimens, cellular starting materials, and preclinical ADME-tox solutions accelerates research with reliable, high-quality products and expertise. Through a comprehensive suite of specialty lab services in genomics, proteomics, cell biology, and molecular pathology, Discovery delivers critical data and insights for biomarker discovery and both retrospective and prospective clinical trials. With a vision to be the most trusted partner in life science research and clinical development, Discovery Life Sciences is committed to advancing life sciences and transforming lives. Visit www.dls.com for more information.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account